Antidepressant agents

From tricyclics to serotonin uptake inhibitors

S. Garattini, C. Barbui, B. Saraceno

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. The number of antidepressant drugs available in the market has grown rapidly in the last few years. The present paper underlines some of the pre-clinical and clinical problems that call close attention from the regulatory authorities when approving new drugs. Methods. We present here a review of the literature. Results. A wide heterogeneity in the action of the various antidepressants precludes any single theory about the pathogenesis and therapy of depression. Antidepressant activity, in fact, may be achieved by acting on a number of different monoaminergic mechanisms. The variety in the neurochemical effects of antidepressants is not reflected in clinical trials, which tend to stereotypy. In many cases clinical trials aim at demonstrating equivalence rather than differences in efficacy. Regulatory authorities should, therefore, pay attention in accepting the equivalence of effects of a new drug in relation to a reference one: most clinical trials of new antidepressant drugs do not have the power to detect clinically relevant differences. Conclusions. Unconventional new pre-clinical tests are needed to generate antidepressants with a different mechanism of action. Clinical studies are needed to promote objective comparative evaluation of the cost, benefits and toxic effects of new antidepressants.

Original languageEnglish
Pages (from-to)1169-1178
Number of pages10
JournalPsychological Medicine
Volume28
Issue number5
DOIs
Publication statusPublished - Sep 1998

Fingerprint

Serotonin Uptake Inhibitors
Antidepressive Agents
Clinical Trials
Poisons
Pharmaceutical Preparations
Cost-Benefit Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Antidepressant agents : From tricyclics to serotonin uptake inhibitors. / Garattini, S.; Barbui, C.; Saraceno, B.

In: Psychological Medicine, Vol. 28, No. 5, 09.1998, p. 1169-1178.

Research output: Contribution to journalArticle

Garattini, S. ; Barbui, C. ; Saraceno, B. / Antidepressant agents : From tricyclics to serotonin uptake inhibitors. In: Psychological Medicine. 1998 ; Vol. 28, No. 5. pp. 1169-1178.
@article{fa82c4a8ea784f0281a4626f8810d2c3,
title = "Antidepressant agents: From tricyclics to serotonin uptake inhibitors",
abstract = "Background. The number of antidepressant drugs available in the market has grown rapidly in the last few years. The present paper underlines some of the pre-clinical and clinical problems that call close attention from the regulatory authorities when approving new drugs. Methods. We present here a review of the literature. Results. A wide heterogeneity in the action of the various antidepressants precludes any single theory about the pathogenesis and therapy of depression. Antidepressant activity, in fact, may be achieved by acting on a number of different monoaminergic mechanisms. The variety in the neurochemical effects of antidepressants is not reflected in clinical trials, which tend to stereotypy. In many cases clinical trials aim at demonstrating equivalence rather than differences in efficacy. Regulatory authorities should, therefore, pay attention in accepting the equivalence of effects of a new drug in relation to a reference one: most clinical trials of new antidepressant drugs do not have the power to detect clinically relevant differences. Conclusions. Unconventional new pre-clinical tests are needed to generate antidepressants with a different mechanism of action. Clinical studies are needed to promote objective comparative evaluation of the cost, benefits and toxic effects of new antidepressants.",
author = "S. Garattini and C. Barbui and B. Saraceno",
year = "1998",
month = "9",
doi = "10.1017/S0033291798007090",
language = "English",
volume = "28",
pages = "1169--1178",
journal = "Psychological Medicine",
issn = "0033-2917",
publisher = "Cambridge University Press",
number = "5",

}

TY - JOUR

T1 - Antidepressant agents

T2 - From tricyclics to serotonin uptake inhibitors

AU - Garattini, S.

AU - Barbui, C.

AU - Saraceno, B.

PY - 1998/9

Y1 - 1998/9

N2 - Background. The number of antidepressant drugs available in the market has grown rapidly in the last few years. The present paper underlines some of the pre-clinical and clinical problems that call close attention from the regulatory authorities when approving new drugs. Methods. We present here a review of the literature. Results. A wide heterogeneity in the action of the various antidepressants precludes any single theory about the pathogenesis and therapy of depression. Antidepressant activity, in fact, may be achieved by acting on a number of different monoaminergic mechanisms. The variety in the neurochemical effects of antidepressants is not reflected in clinical trials, which tend to stereotypy. In many cases clinical trials aim at demonstrating equivalence rather than differences in efficacy. Regulatory authorities should, therefore, pay attention in accepting the equivalence of effects of a new drug in relation to a reference one: most clinical trials of new antidepressant drugs do not have the power to detect clinically relevant differences. Conclusions. Unconventional new pre-clinical tests are needed to generate antidepressants with a different mechanism of action. Clinical studies are needed to promote objective comparative evaluation of the cost, benefits and toxic effects of new antidepressants.

AB - Background. The number of antidepressant drugs available in the market has grown rapidly in the last few years. The present paper underlines some of the pre-clinical and clinical problems that call close attention from the regulatory authorities when approving new drugs. Methods. We present here a review of the literature. Results. A wide heterogeneity in the action of the various antidepressants precludes any single theory about the pathogenesis and therapy of depression. Antidepressant activity, in fact, may be achieved by acting on a number of different monoaminergic mechanisms. The variety in the neurochemical effects of antidepressants is not reflected in clinical trials, which tend to stereotypy. In many cases clinical trials aim at demonstrating equivalence rather than differences in efficacy. Regulatory authorities should, therefore, pay attention in accepting the equivalence of effects of a new drug in relation to a reference one: most clinical trials of new antidepressant drugs do not have the power to detect clinically relevant differences. Conclusions. Unconventional new pre-clinical tests are needed to generate antidepressants with a different mechanism of action. Clinical studies are needed to promote objective comparative evaluation of the cost, benefits and toxic effects of new antidepressants.

UR - http://www.scopus.com/inward/record.url?scp=0031687572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031687572&partnerID=8YFLogxK

U2 - 10.1017/S0033291798007090

DO - 10.1017/S0033291798007090

M3 - Article

VL - 28

SP - 1169

EP - 1178

JO - Psychological Medicine

JF - Psychological Medicine

SN - 0033-2917

IS - 5

ER -